Author Affiliations: Department of Medicine, University of California, San Francisco.
Minder et al disagree that statins for primary prevention are an example of a widely used medication with no known benefit and definite risks. Although they concede that the evidence that statins prolong survival is “less than robust,” they state that such evidence cannot be expected from trials in which patients were only treated for a few years. To support their belief in statin use for primary prevention they cite a meta-analysis
(Brugts et al1) that includes data from studies of both primary and secondary prevention, where most of the benefit occurred in the studies of secondary prevention. Importantly, Minder et al do not acknowledge the commonly reported adverse effects associated with statins, including memory loss, muscle pains, weakness, and liver function abnormalities.
Redberg RF, Katz M, Grady D. To Make the Case—Evidence Is Required: Comment on “Making the Case for Selective Use of Statins in the Primary Prevention Setting”. Arch Intern Med. 2011;171(17):1594. doi:10.1001/archinternmed.2011.409
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: